AIM ImmunoTech
30 hedge funds and large institutions have $3.01M invested in AIM ImmunoTech in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 6 closing their positions.
0.63% less ownership
Funds ownership: 9.9% → 9.27% (-0.63%)
3% less funds holding
Funds holding: 31 → 30 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
66% less capital inflows, than outflows
Capital inflows: $64.8K | Capital outflows: $191K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$21.6K |
| 2 |
DRW Securities
Chicago,
Illinois
|
+$17.9K |
| 3 |
Jane Street
New York
|
+$10.7K |
| 4 |
D.B. Root & Company
Pittsburgh,
Pennsylvania
|
+$5.84K |
| 5 |
Renaissance Technologies
New York
|
+$4.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$84.5K |
| 2 |
BlackRock
New York
|
-$52.9K |
| 3 |
Rockefeller Capital Management
New York
|
-$17K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$12.9K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$9K |
AIM Hedge Fund Activity: Q2 2023 in Review
30 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q2 2023, worth a combined $3.01M — up 47% from $2.05M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of AIM and 5 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, adding an estimated $21.6K. The largest seller was Morgan Stanley, cutting an estimated $84.5K.
- 30 institutional investors held AIM ImmunoTech (AIM) as of Q2 2023, down from 31 in Q1 2023.
- Funds reported $3.01M of AIM ImmunoTech stock for Q2 2023, up 47% quarter-over-quarter.
- 5 funds opened new AIM ImmunoTech positions in Q2 2023 and 6 closed out, a net change of -1 holder.
- The largest AIM ImmunoTech buyer in Q2 2023 was Susquehanna International Group, an estimated $21.6K added.
- The largest AIM ImmunoTech seller in Q2 2023 was Morgan Stanley, an estimated $84.5K sold.
Based on aggregated 13F filings for Q2 2023.